Novo Nordisk Bets Its Entire Operation on OpenAI
What Happened
Novo Nordisk announced a partnership with OpenAI to apply AI across drug discovery, clinical analysis, manufacturing, supply chain, and corporate functions, with pilots running now and full integration targeted by end of 2026. OpenAI will also help upskill Novo's global workforce. Novo joins Sanofi, Moderna, Eli Lilly, and others in signing OpenAI pharma deals.
My Take
The headline says "drug discovery," but the real move is the enterprise-wide scope — and that's the pattern worth watching. OpenAI isn't selling pharma a research tool; it's selling an operating layer for the whole company, plus the training to make staff dependent on it. That's far stickier than a software license. The risk Novo is underwriting: deep operational dependence on a single, fast-moving vendor that could change pricing or priorities overnight. Expect a wave of "AI vendor concentration" questions from boards and auditors by 2027.
Read Original Source